Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

TYRVAYA®Positive

AI Analysis

Summary

Harrow announced the acquisition of global rights to TYRVAYA®, the first and only FDA-approved nasal spray for dry eye disease, expanding its commercial portfolio.

Outcome Details

Harrow acquires global rights to TYRVAYA®

Importance:7/10

Sentiment:

0.70

acquisitionFDA-approveddermatologyophthalmology

Related Companies

$HROW

Read the original article

Published by yahoo_finance on August 6, 2026 11:00 AM

Read Original